Perturbation of Fetal Liver Hematopoietic Stem and Progenitor Cell Development by Trisomy 21

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2012 Oct 10

PMID 23045701

Citations 84

Authors

Anindita Roy

Gillian Cowan

Adam J Mead

Sarah Filippi

Georg Bohn

Aristeidis Chaidos

Oliver Tunstall

Jerry K Y Chan

Mahesh Choolani

Phillip Bennett

Sailesh Kumar

Deborah Atkinson

Josephine Wyatt-Ashmead

Ming Hu

Michael P H Stumpf

Katerina Goudevenou

David OConnor

Stella T Chou

Mitchell J Weiss

Anastasios Karadimitris

Sten Eirik Jacobsen

Paresh Vyas

Irene Roberts

Affiliations

Soon will be listed here.

Abstract

The 40-fold increase in childhood megakaryocyte-erythroid and B-cell leukemia in Down syndrome implicates trisomy 21 (T21) in perturbing fetal hematopoiesis. Here, we show that compared with primary disomic controls, primary T21 fetal liver (FL) hematopoietic stem cells (HSC) and megakaryocyte-erythroid progenitors are markedly increased, whereas granulocyte-macrophage progenitors are reduced. Commensurately, HSC and megakaryocyte-erythroid progenitors show higher clonogenicity, with increased megakaryocyte, megakaryocyte-erythroid, and replatable blast colonies. Biased megakaryocyte-erythroid-primed gene expression was detected as early as the HSC compartment. In lymphopoiesis, T21 FL lymphoid-primed multipotential progenitors and early lymphoid progenitor numbers are maintained, but there was a 10-fold reduction in committed PreproB-lymphoid progenitors and the functional B-cell potential of HSC and early lymphoid progenitor is severely impaired, in tandem with reduced early lymphoid gene expression. The same pattern was seen in all T21 FL samples and no samples had GATA1 mutations. Therefore, T21 itself causes multiple distinct defects in FL myelo- and lymphopoiesis.

Citing Articles

Childhood leukaemia in Down's syndrome primed by blood-cell bias.

Malinge S Nature. 2024; 634(8032):40-42.

PMID: 39322696 DOI: 10.1038/d41586-024-02785-9.

Single-cell multi-omics map of human fetal blood in Down syndrome.

Marderstein A, De Zuani M, Moeller R, Bezney J, Padhi E, Wong S Nature. 2024; 634(8032):104-112.

PMID: 39322663 PMC: 11446839. DOI: 10.1038/s41586-024-07946-4.

Down syndrome-associated leukaemias: current evidence and challenges.

Mason N, Cahill H, Diamond Y, McCleary K, Kotecha R, Marshall G Ther Adv Hematol. 2024; 15:20406207241257901.

PMID: 39050114 PMC: 11268035. DOI: 10.1177/20406207241257901.

GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development.

Takasaki K, Chou S Adv Exp Med Biol. 2024; 1459:261-287.

PMID: 39017848 DOI: 10.1007/978-3-031-62731-6_12.

Patterns of Aneuploidy and Signaling Consequences in Cancer.

Zhakula-Kostadinova N, Taylor A Cancer Res. 2024; 84(16):2575-2587.

PMID: 38924459 PMC: 11325152. DOI: 10.1158/0008-5472.CAN-24-0169.

References

Sanz E, Munoz-A N, Monserrat J, Van-Den-Rym A, Escoll P, Ranz I . Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. Proc Natl Acad Sci U S A. 2010; 107(13):5925-30. PMC: 2851857. DOI: 10.1073/pnas.0907942107. View

Klusmann J, Li Z, Bohmer K, Maroz A, Koch M, Emmrich S . miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 2010; 24(5):478-90. PMC: 2827843. DOI: 10.1101/gad.1856210. View

Olson L, Roper R, Sengstaken C, Peterson E, Aquino V, Galdzicki Z . Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet. 2007; 16(7):774-82. DOI: 10.1093/hmg/ddm022. View

Hitzler J, Cheung J, Li Y, Scherer S, Zipursky A . GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003; 101(11):4301-4. DOI: 10.1182/blood-2003-01-0013. View

Conti A, Fabbrini F, DAgostino P, Negri R, Greco D, Genesio R . Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics. 2007; 8:268. PMC: 1964766. DOI: 10.1186/1471-2164-8-268. View

Mansson R, Hultquist A, Luc S, Yang L, Anderson K, Kharazi S . Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity. 2007; 26(4):407-19. DOI: 10.1016/j.immuni.2007.02.013. View

Salek-Ardakani S, Smooha G, de Boer J, Sebire N, Morrow M, Rainis L . ERG is a megakaryocytic oncogene. Cancer Res. 2009; 69(11):4665-73. DOI: 10.1158/0008-5472.CAN-09-0075. View

Majeti R, Park C, Weissman I . Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2008; 1(6):635-45. PMC: 2292126. DOI: 10.1016/j.stem.2007.10.001. View

Whitlock J, Sather H, Gaynon P, Robison L, Wells R, Trigg M . Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005; 106(13):4043-9. DOI: 10.1182/blood-2003-10-3446. View

10.

Wechsler J, Greene M, McDevitt M, Anastasi J, Karp J, Le Beau M . Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002; 32(1):148-52. DOI: 10.1038/ng955. View

11.

Alford K, Reinhardt K, Garnett C, Norton A, Bohmer K, von Neuhoff C . Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011; 118(8):2222-38. DOI: 10.1182/blood-2011-03-342774. View

12.

Mao R, Zielke C, Zielke H, Pevsner J . Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics. 2003; 81(5):457-67. DOI: 10.1016/s0888-7543(03)00035-1. View

13.

Lange B, Kobrinsky N, Barnard D, Arthur D, Buckley J, Howells W . Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998; 91(2):608-15. View

14.

Li Z, Godinho F, Klusmann J, Garriga-Canut M, Yu C, Orkin S . Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005; 37(6):613-9. DOI: 10.1038/ng1566. View

15.

Antonarakis S, Lyle R, Dermitzakis E, Reymond A, Deutsch S . Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet. 2004; 5(10):725-38. DOI: 10.1038/nrg1448. View

16.

Bourquin J, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P . Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006; 103(9):3339-44. PMC: 1413912. DOI: 10.1073/pnas.0511150103. View

17.

Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen C . Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005; 121(2):295-306. DOI: 10.1016/j.cell.2005.02.013. View

18.

Roper R, Reeves R . Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006; 2(3):e50. PMC: 1420680. DOI: 10.1371/journal.pgen.0020050. View

19.

Klusmann J, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C . Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008; 111(6):2991-8. PMC: 2265448. DOI: 10.1182/blood-2007-10-118810. View

20.

MacLean G, Menne T, Guo G, Sanchez D, Park I, Daley G . Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A. 2012; 109(43):17567-72. PMC: 3491455. DOI: 10.1073/pnas.1215468109. View